Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
19:55:59 EDT Fri 18 Jul 2025
Enter Symbol
or Name
USA
CA



Q:PRTC - PURETECH HEALTH PLC SPON ADS EACH REP 10 ORD SHS - Website unknown - click to update
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
PRTC - Q0.118.50·24.960.419.6673+0.92734.90.7122919.76  19.76  19.667324.99  13.3016:04:11Jul 1715 min RT 2¢

Recent Trades - Last 10 of 29
Time ETExPriceChangeVolume
16:04:11Q19.1250.6251
16:00:00Q19.1250.6251
15:59:24Q18.690.1910
15:57:54Q18.920.421
15:57:54Q18.900.401
15:38:20Q19.200.701
14:33:08Q19.49810.99811
14:33:08Q19.49810.99811
13:35:39Q19.751.251
13:32:36Q19.511.011

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2025-07-17 07:05U:PRTCNews ReleasePureTech Founded Entity Seaport Therapeutics Announces First Patient Dosed in Phase 2b BUOY-1 Study of GlyphAllo(TM) (SPT-300) in Major Depressive Disorder (MDD), With or Without Anxious Distress
2025-07-16 02:00U:PRTCNews ReleasePureTech Announces Leadership Transition
2025-07-08 12:45U:PRTCNews ReleasePureTech Announces Board Change
2025-06-26 02:00U:PRTCNews ReleasePureTech Founded Entity Vor Bio Announces Exclusive Global License Agreement with RemeGen for Late-Stage Autoimmune Asset and $175 Million Private Placement
2025-06-16 12:59U:PRTCNews ReleasePureTech Health: Results of Annual General Meeting
2025-05-22 07:00U:PRTCNews ReleasePureTech to Present at the Jefferies Global Healthcare Conference
2025-05-20 17:15U:PRTCNews ReleasePureTech's Deupirfenidone (LYT-100) Demonstrates Strong and Durable Efficacy as a Monotherapy with Favorable Tolerability in Phase 2b ELEVATE IPF Trial
2025-05-09 07:00U:PRTCNews ReleasePureTech Announces Publication of New Research Highlighting Untold Experiences of People Living with Idiopathic Pulmonary Fibrosis (IPF)
2025-05-01 07:00U:PRTCNews ReleasePureTech to Present Results from Phase 2b ELEVATE IPF Trial of Deupirfenidone (LYT-100) at the American Thoracic Society International Conference
2025-04-30 02:00U:PRTCNews ReleasePureTech Announces Annual Results for Year Ended December 31, 2024
2025-04-23 02:00U:PRTCNews ReleasePureTech Health: Notice of Results
2025-04-09 02:00U:PRTCNews ReleasePureTech Appoints Peel Hunt as Joint UK Corporate Broker
2025-04-07 12:16U:PRTCNews ReleasePureTech Health plc Statement Regarding Press Speculation
2025-03-11 07:05U:PRTCNews ReleasePureTech Founded Entity Seaport Therapeutics Appoints Robert J. Hombach to its Board of Directors as Audit Committee Chair
2025-02-25 07:27U:PRTCNews ReleasePureTech to Present at the Leerink Partners Global Healthcare Conference
2025-02-12 07:05U:PRTCNews ReleasePureTech Founded Entity Seaport Therapeutics Announces the Publication of New Research Demonstrating Increased Lymphatic Transport with up to 55 Percent Drug Absorption via Lymphatics with GlyphTM Platform
2025-01-27 02:00U:PRTCNews ReleasePureTech Founded Vedanta Biosciences Publishes Additional Phase 2 VE303 Results in Nature Medicine
2025-01-09 07:00U:PRTCNews ReleasePureTech Receives FDA Fast Track Designation for LYT-200 in Acute Myeloid Leukemia (AML)
2025-01-08 07:00U:PRTCNews ReleasePureTech to Present at 43rd Annual J.P. Morgan Healthcare Conference
2025-01-06 02:00U:PRTCNews ReleasePureTech Appoints UBS as UK Corporate Broker